Drug comparisons
Linagliptin vs Repaglinide
Compare Linagliptin (Tradjenta) vs Repaglinide for type 2 diabetes. Differences in mechanism, hypoglycemia risk, dosing, and patient suitability.
No comparison dimensions are available for this page.
Clinical context
This comparison is triggered when choosing an add-on oral agent for type 2 diabetes after metformin, balancing postprandial control against hypoglycemia risk and dosing convenience.
Bottom line
Linagliptin is often preferred for lower hypoglycemia risk and simpler dosing, but Repaglinide may suit patients needing targeted mealtime glucose control.
All medication comparisons